Education
About Us
Working with TipRanks
Follow Us
Glaukos Corp. (GKOS)
:GKOS
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.52Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 30, 2025
|% Change Since: 1.29%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
Glaukos demonstrated strong financial performance with record revenues and robust growth in the iDose TR and international glaucoma franchises. However, challenges such as the impact of LCD restrictions on the U.S. stent business and Photrexa revenue impact were noted. Despite these challenges, the company maintains a strong financial position and continues to advance promising pipeline products.Company Guidance
During the Glaukos Corporation's First Quarter 2025 Financial Results Conference Call, the company reported record consolidated net sales of $106.7 million, marking a 25% increase on a reported basis and 26% on a constant currency basis compared to the same quarter a year ago. The company reaffirmed its full-year 2025 net sales guidance range of $475 million to $485 million. The U.S. glaucoma franchise achieved record first-quarter net sales of $59.1 million, reflecting a 41% year-over-year growth, driven by the adoption of iDose TR. International interventional glaucoma sales reached $29 million, showing a 15% increase on a reported basis and 19% on a constant currency basis. The corneal health franchise delivered $18.5 million in net sales, with Photrexa contributing $15.4 million. The company remains optimistic about its pipeline, including the FDA's review of Epioxa and the commencement of a pivotal study for PRESERFLO MicroShunt. Glaukos ended the quarter with over $303 million in cash and equivalents and no debt.Record-Breaking Revenue and Growth
Glaukos reported record first quarter consolidated net sales of $106.7 million, up 25% on a reported basis, or 26% on a constant currency basis versus the year ago quarter. The company reaffirmed its full-year 2025 net sales guidance range of $475 million to $485 million.
Strong Performance of iDose TR
The U.S. glaucoma franchise delivered record first quarter net sales of $59.1 million, with 41% year-over-year growth driven by the adoption of iDose TR.
International Glaucoma Franchise Growth
International glaucoma franchise delivered record net sales of $29 million with year-over-year growth of 15% on a reported basis and 19% on a constant currency basis.
Strong Financial Position
Glaukos ended the first quarter of 2025 with a strong capital position, holding cash and equivalents of more than $303 million and no debt.
FDA Acceptance of Epioxa NDA
FDA has accepted the NDA for Epioxa, a next-generation corneal cross-linking therapy, for review, with a PDUFA date established for October 20, 2025.
---
GKOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GKOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2025 | $94.25 | $83.54 | -11.36% |
Feb 20, 2025 | $157.36 | $125.88 | -20.01% |
Nov 04, 2024 | $131.38 | $127.86 | -2.68% |
Jul 31, 2024 | $117.17 | $117.61 | +0.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Glaukos Corp. (GKOS) report earnings?
Glaukos Corp. (GKOS) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Glaukos Corp. (GKOS) earnings time?
Glaukos Corp. (GKOS) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GKOS EPS forecast?
GKOS EPS forecast for the fiscal quarter 2025 (Q2) is -0.26.
---